July 2011
Has been granted €1.4 million government loan for acute myeloid leukemia program.
September 2010
Closed first financing round with Thuja Capital.
August 2010
Receives substantial grant from EUROTRANS-BIO.
December 2009
Receives permission from the Dutch regulatory authority CCMO for first clinical study using the DCOne vaccine technology platform.
October 2009
Release Master Cell Bank lead product DCOne by PharmaCell, CMO for DCPrime.
January 2009
Granted SME status by EMEA.
November 2008
Acquired Senter SI2 grant from Min. of Economic Affairs for TARAC project, together with BioFocus/Galapagos, AMC, VUmc and University of Ghent, for a drug discovery project based on DCPrime’s cell lines.
April 2007
Closed contract with SIGNIFIX to assist in development of the GMP production process for lead product DCOne and implement ISO/GLP/GMP quality management systems for compliance to required regulatory and quality standards within DCPrime’s laboratories.
December 2006
Acquired Senter International Collaboration subsidy from Min. of Economic Affairs for STAVAC project, partners PharmaCell (Maastricht), VUmc (Amsterdam), INCResearch (USA), CyGenics (Singapore): covers development and clinical validation of lead product DCOne in prostate cancer patients.
July 2006
Closed contract with company BruCells SA/NV, Brussels, for a 3-year collaboration on application of DCPrime’s dendritic cell platform for clinical studies with a fusion product consisting of DCOne with glioblastoma and renal cell carcinoma cells.
June 2005
Acquired BioPartner subsidy from Min. Of Economic Affairs, for feasibility studies and preparation of work leading to clinical studies.
March 2005
Founded BV by Prof Dr Ada Kruisbeek (CEO) and Prof. Dr Rik Scheper, with additional shares being held by VU medical center Boelevaar Holding and Drug Discovery Factory.
Has been granted €1.4 million government loan for acute myeloid leukemia program.
September 2010
Closed first financing round with Thuja Capital.
August 2010
Receives substantial grant from EUROTRANS-BIO.
December 2009
Receives permission from the Dutch regulatory authority CCMO for first clinical study using the DCOne vaccine technology platform.
October 2009
Release Master Cell Bank lead product DCOne by PharmaCell, CMO for DCPrime.
January 2009
Granted SME status by EMEA.
November 2008
Acquired Senter SI2 grant from Min. of Economic Affairs for TARAC project, together with BioFocus/Galapagos, AMC, VUmc and University of Ghent, for a drug discovery project based on DCPrime’s cell lines.
April 2007
Closed contract with SIGNIFIX to assist in development of the GMP production process for lead product DCOne and implement ISO/GLP/GMP quality management systems for compliance to required regulatory and quality standards within DCPrime’s laboratories.
December 2006
Acquired Senter International Collaboration subsidy from Min. of Economic Affairs for STAVAC project, partners PharmaCell (Maastricht), VUmc (Amsterdam), INCResearch (USA), CyGenics (Singapore): covers development and clinical validation of lead product DCOne in prostate cancer patients.
July 2006
Closed contract with company BruCells SA/NV, Brussels, for a 3-year collaboration on application of DCPrime’s dendritic cell platform for clinical studies with a fusion product consisting of DCOne with glioblastoma and renal cell carcinoma cells.
June 2005
Acquired BioPartner subsidy from Min. Of Economic Affairs, for feasibility studies and preparation of work leading to clinical studies.
March 2005
Founded BV by Prof Dr Ada Kruisbeek (CEO) and Prof. Dr Rik Scheper, with additional shares being held by VU medical center Boelevaar Holding and Drug Discovery Factory.